Fig. 3: IDH1 treatment increases multimer binding and cytokine production in CD8 T cells. | Oncogene

Fig. 3: IDH1 treatment increases multimer binding and cytokine production in CD8 T cells.

From: Glioma immunotherapy enhancement and CD8-specific sialic acid cleavage by isocitrate dehydrogenase (IDH)-1

Fig. 3

A GL26 target lysis by an H-2Kb reactive T cell hybridoma effectors after 7 h, +/−5 mM oxalomalic acid (OMA); *p < 0.05, ***p < 0.005. B Parental GL26, IDH1 and IDH1R132H transfectant lysis over time by H-2Kb reactive hybridoma effectors (E:T ratio 10:1); *p < 0.05. C Anti-IDH1 antibody increased early lysis of GL26-IDH1R132H targets by CTL from GL26-vaccinated mice. Anti-IDH1 had no impact on CTL lysis of 7 and 16 h targets (4 h with E:T = 10:1 E:T is shown; *p < 0.05). D Enhanced binding of IDH1-treated CD8 T cells to pMHC I dextramers. E IDH1-treated C57BL/6 (B6) mouse CD8 T cells producing IFNγ expand following stimulation with an H-2Kb/TVSEFLKL Survivin dextramer + anti-CD28 antibody. F B6 CD8 T cell IFNγ production over time stimulated by H-2Kb/SVYDFFVWL Trp-2 dextramer + anti-CD28, after treatment with IDH1, neuraminidase, or control (Untreated or No Rx = [dextramer+anti-CD28], no IDH1-treatment). G 10-h compilation of distinct pMHC I dextramer + anti-CD28 stimulation.

Back to article page